BiotechTube
Home/Pipeline/Heparin-based candidate for Alzheimer's

Heparin-based candidate for Alzheimer's

Alzheimer's Disease

Pre-clinicalActive

Key Facts

Indication
Alzheimer's Disease
Phase
Pre-clinical
Status
Active
Company
Intellihep

About Intellihep

IntelliHep is a private, pre-clinical stage biotech exploiting a proprietary platform to engineer novel heparin-based compounds. Its core focus is on in-house development of lead candidates for Alzheimer's disease and cancer, with broader potential applications in inflammation, angiogenesis, and regenerative medicine. Founded in 2019 and based in London, the company is currently pre-revenue and built on a team with deep expertise in heparin glycobiology and chemistry.

View full company profile

Therapeutic Areas

NeurodegenerationOncologyInflammationRegenerative Medicine

Other Alzheimer's Disease Drugs

DrugCompanyPhase
ALZN002Alzamend NeuroPreclinical
P021Phanes BiotechPreclinical
PB43DPhanes BiotechPreclinical
UB-311VaxxinityPhase 2
LecanemabBioArcticLaunched
BAN2401BioArcticPreclinical
itMSCsStemedica Cell TechnologiesClinical Development
Aucuba-001Aucuba SciencesPreclinical
ALTA Drug SeriesAlteron TherapeuticsPreclinical
NTRX-07NeuroTherapiaPhase 2
3D Neuronal Disease ModelsBioTalentumResearch
Not Publicly DisclosedCerecinPhase 1/2